Back to search

Article

Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes.

2025-06-04

Abstract excerpt

LBA5006 Background: NIRA is a highly selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP)-1/2. In the MAGNITUDE trial, NIRA + AAP significantly improved radiographic progression-free survival (rPFS) in HRR gene–altered metastatic castration-resistant prostate cancer. The double-blind, placebo (PBO)-controlled AMPLITUDE trial (NCT04497844) evaluated the efficacy and safety of NIRA + AAP in HRR gene...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
463c4669-ebde-5674-abd1-610eaf9b57d7
DOI
10.1200/jco.2025.43.17_suppl.lba5006
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes.DOI 10.1200/jco.2025.43.17_suppl.lba5006
Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study ResultsSemantic proximity
PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review.Semantic proximity
First-line combination treatment with PARP and androgen receptor–signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United StatesSemantic proximity
BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes.Semantic proximity
Olaparib combined with abiraterone in HRR-mutated metastatic hormone-sensitive prostate cancer: a single-arm phase II trial.Semantic proximity
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway).Semantic proximity
PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic LandscapeSemantic proximity
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.Semantic proximity
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring aBRCA1orBRCA2Gene AlterationSemantic proximity
Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testingSemantic proximity
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 StudySemantic proximity
The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis.Semantic proximity
Select a neighboring publication to make it the new centre.